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Abstract
Background. Diabetes mellitus (DM) type 1 is an
important contributor to end-stage renal disease
(ESRD) among younger transplant recipients.
However, little is known about the changes in
epidemiological characteristics of this population.
Especially, time to reach ESRD may have changed in
type 1 diabetic patients referred for transplantation,
resulting in higher age at time of grafting. Such time
trends may allow anticipating future developments
regarding the demand for organ replacement in this
patient group.
Methods. We retrospectively analysed 173 patients
with type 1DM undergoing renal transplantation at
our institution, stratiﬁed into four groups according
to year of reaching ESRD (A¼ 1973–1983,
B¼ 1984–1990, C¼ 1991–1995 and D¼ 1996–2002).
For each group we determined age at diagnosis of
DM, age at time of reaching ESRD and age at time
of transplantation. From these data, the interval from
diagnosis of DM to ESRD and from ESRD to
transplantation was calculated. The results were
analysed in relation to gender, year of and age at
onset of diabetes.
Results. Patients reaching ESRD in more recent years
(group D) tended to be both younger at diagnosis of
DM and older when reaching ESRD, resulting in
higher mean age at transplantation (35.0, 37.5, 39.6
and 41.0 years in groups A, B, C and D, respectively).
Accordingly, median duration to ESRD has signiﬁ-
cantly been prolonged over the last ﬁve decades in
patients with type 1DM undergoing renal transplanta-
tion (group A: 21.0, B: 20.7, C: 22.3 and D: 28.5 years;
P<0.0001), this ﬁnding being more pronounced in
female patients.
Conclusions. The results of our analysis are
compatible with a change in epidemiology in patients
undergoing kidney transplantation. Older age at
time of reaching ESRD may impact signiﬁcantly on
the demand for renal grafts, as patients are
already clearly older nowadays when being trans-
planted. From our data it cannot be concluded
whether this development is due to a change in the
progression of diabetic nephropathy or may simply
reﬂect a change in the selection of type 1 diabetic
patients referred for transplantation.
Keywords: diabetes mellitus type 1; diabetic
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Introduction
Epidemiological data suggest that the incidence of
nephropathy among patients with type 1 diabetes is
stable [1] or even dropping [2–4]. However, as the
incidence of diabetes mellitus (DM) continues to
increase [5], diabetic nephropathy has become a major
cause of renal failure in the Western world [6,7]. The
frequency of diabetic patients initiated on renal
replacement therapy very much depends on both the
referral criteria and the rate of progression from onset
of diabetes to end-stage renal disease (ESRD). Thus, it
is of paramount socioeconomic interest whether the
epidemiological characteristics and the course of
diabetic nephropathy in patients referred for transplan-
tation has changed over the last decades. Both changes
in the criteria for eligibility to receive a renal allograft
and improvements in diagnosing, managing and treat-
ing diabetic patients may have resulted in a change in
characteristics of patients referred for transplantation
and their course of progression to renal failure. Better
antihypertensive therapy [8], the use of angiotensin-
converting enzyme (ACE) inhibitors [9–11], intensive
insulin treatment [12] and the combined implementa-
tion of these measures [13] seem to impact positively
on the course of diabetic nephropathy in general.
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However, no long-term data are available on the
progression to ESRD for the subgroup of patients
that undergo kidney transplantation. Therefore, we
have analysed the epidemiological characteristics of
type 1 diabetics among our transplant patient popula-
tion regarding temporal changes over the last decades
by dividing them into groups according to the year they
had reached ESRD.
Subjects and methods
The present study is a retrospective chart analysis of all
patients with type 1DM which were transplanted at the
university hospital of Zurich (USZ) from May 1974 through
July 2002. Our institution is the only transplant centre
for Zurich, as well as for the eastern and southern part of
Switzerland, exclusively covering an area with a mostly
Caucasian population of about 2 million people. Patients
transplanted at the USZ have been diagnosed and treated for
chronic renal failure either by ourselves or were referred by
nephrologists practising in the residential areas of the patients
analysed in this study. Medical records of all patients
undergoing renal transplantation at the USZ are collected,
updated and archived at our institution. From these central
records, patients with the diagnosis of type 1DM were
identiﬁed by personnel not involved in further data analysis.
The main criteria for identiﬁcation were the diagnosis made
by the referring physician along with a typical medical history
of acute onset of hyperglycaemia and insulin dependence.
Seven patients were excluded because of incomplete or
ambiguous data. The primary end-point of our analysis was
the time interval between onset of DM and the occurrence of
ESRD. The time point of onset of diabetes was based on the
date of diagnosis as noted in the medical records of
the referring physician. ESRD was deﬁned by the initiation
of dialysis treatment or the performance of ﬁrst renal
transplantation (mainly for subjects receiving a kidney
from a living donor). Secondary end-points were age at
onset of DM and ESRD. Patients were stratiﬁed into
four groups according to the year of onset of ESRD
(A¼ 1973–1983, B¼ 1984–1990, C¼ 1991–1995 and
D¼ 1996–2002). The intervals in each stratum were chosen
to achieve groups balanced for time span covered and
strata size. Also, we aimed to assign subjects in order to
have one group that, at least in theory, was substantially
‘exposed’ to newer therapeutic strategies, i.e. the use of ACE
inhibitors, or intensiﬁed insulin therapy. As the number of
patients referred for transplantation was increasing over time,
most probably reﬂecting a more liberal referral policy in latter
years, the resulting groups are not homogenous for both
criteria (number of patients and time span). However, the
outcome of our analysis was found to be independent of how
groups were formed.
Data are presented as means±SD and as range, unless
indicated otherwise. Time between diagnosis of DM to ESRD
is given as median and 95% conﬁdence interval by group
and displayed graphically using a failure plot that reverses
the y-axis to show the number of failures rather than
the number of survivors. Comparison between groups
was performed with ANOVA and post-test analysis with
Kramer–Tukey test.
Results
Among the 1779 patients that had undergone renal
transplantation at our centre since 1973, 180 (10.1%)
were identiﬁed from central records with the diagnosis
of type 1DM and were evaluated for inclusion
into our analysis. Of the 173 patients available for
analysis, all are of Caucasian origin. They developed
DM between 1944 and 1983, covering a timeframe
of almost 40 years. Some 138 patients underwent
transplantation of a kidney in combination with either
a pancreas (n¼ 133, since January 1974) or pancreatic
islet cells (n¼ 6, since January 2000). The remainder
received a kidney transplant alone (n¼ 35), with
four of them having a living donor source of
their organ. The 173 patients were stratiﬁed into
groups A–D according to the year of ESRD occur-
rence. Twenty-four patients underwent transplantation
without prior dialysis treatment. The characteristics
of the entire group, as well as of the individual strata,
are shown in Table 1. The ratio of male to female
patients was even for the combined groups, whereas
a predominance of women was noted in strata A and D.
Mean age at diagnosis of type 1DM was 12.7 years for
the entire cohort, the oldest patients belonging to group
C. Patients reaching ESRD in the most recent period
were clearly younger at onset of DM compared with all
other groups. In contrast, patients with the most recent
onset of renal failure from diabetic nephropathy
(group D) were signiﬁcantly older at time of reaching
ESRD compared with all other groups (P¼ 0.0038,
Table 1). Consequently, the time to ESRD after onset
of DM became increasingly longer in patients diag-
nosed with diabetes in more recent years (P<0.0001,
Table 1). The cumulative incidence of ESRD in this
population of patients with DM type 1 undergoing
kidney transplantation over time is shown graphically
in Figure 1. The percentage of patients having reached
ESRD 20 years after diagnosis of type 1DMwas 45.9 in
group A, 46.0 in group B and 25.5 in group C.
In contrast, the prevalence of ESRD after 20 years
of diabetes in group D was only 12.8% (log-rank
P<0.0001). Finally, the slower progression to ESRD in
type 1DM patients diagnosed in more recent years
resulted in a higher age of these patients at time of
transplantation (P¼ 0.010, Table 1).
In order to identify potential epidemiological factors
associated with the observed differences in progression
to ESRD, we further analysed our data. As the male
to female ratio was unequal among individual strata,
we wondered whether gender difference might
account for the results described above. Therefore,
we separately analysed our data for male and female
patients regarding age at onset of diabetes, age at
reaching ESRD and the interval between these events.
As a cohort, female patients were 2.6 years younger
compared with men at onset of diabetes (P¼ 0.022),
consistent among all groups (data not shown).
In contrast, women developed end-stage renal failure
1.5 years earlier than men. Consequently, female
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patients, in general, had a slightly longer interval from
onset of diabetes to reaching ESRD. However, this
ﬁnding was inconsistent when analysed among groups
according to period of reaching ESRD. Another
possible factor that may have affected time of progres-
sion to renal failure is age at diagnosis of diabetes.
As mentioned earlier, patients developing ESRD in
more recent years (i.e. group D) tended to be younger
when they were diagnosed with diabetes. Indeed,
a weak correlation between age at diagnosis of DM
and time to reach renal failure was detectable for all
four groups (Figure 2; r¼0.37). However, for every
given age, time to develop ESRD tended to be longer in
patients with more recent occurrence of renal failure.
This conclusion may be ﬂawed as it is prone to selection
bias. Patients with a very long duration of diabetes
at onset of ESRD are more likely to be considered
for transplantation when being diagnosed with DM
at younger age, as they won’t be as old at time
of transplant as a patient with onset of DM at higher
age and slow progression to ESRD. Finally, age
at diagnosing diabetes may be related to the year at
onset of the condition. As shown in Figure 3, patients
tended to be younger when diagnosed with diabetes in
earlier times (r¼ 0.32). On the other hand, when
analysed separately according to year of reaching
ESRD, patients with more recent occurrence of renal
failure were younger in general at any given year of DM
diagnosis. Again, a note of caution needs to be raised
and the probability of selection bias be considered. The
likelihood to be transplanted in 1974 or beyond (when
our transplant programme was initiated), and thus
being included in our analysis, was higher for younger
patients diagnosed with DM in the later years of the
1940s (or early years of the 1950s). Being of higher age
at onset of diabetes in 1947, for example, would prob-
ably have precluded individuals from transplantation
>27 years later, as they most likely would have been
considered to be too old.
Discussion
The results of this retrospective analysis, covering a
period of almost 40 years, reveal relevant temporal
trends in the epidemiological characteristics of patients
with type 1DM referred for renal transplantation.
Patients having reached ESRD more recently are
signiﬁcantly older at time of both renal failure and
transplantation compared with all other groups.
Moreover, a signiﬁcant prolongation from onset of
diabetes to ESRD in transplant patients with more
recent development of renal failure (group D,
1996–2002) can be observed.
The ﬁndings of our study may be accounted for by
several causes, the most likely being changes in the
selection and referral criteria of patients with diabetic
nephropathy for transplantation. Speciﬁcally, medical
practice with regard to acceptance of older patients
and diabetics with polymorbidity may have changed
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considerably over time. In addition, the epidemiology
of type 1 diabetes and the ‘natural course’ of
diabetic kidney disease may have changed over the
last decades due to environmental and medical
factors. Epidemiological factors, such as age at onset
of diabetes, may be of importance in the development
of the disease and its related complications. Indeed,
our analysis revealed a clear trend to younger age at
diagnosis of diabetes in patients referred for transplan-
tation in the more recent past (Table 1) and an inverse
correlation between age at diagnosis of DM and time to
reach ESRD (Figure 2). These ﬁndings suggest that
patients diagnosed with diabetes at younger age have
a more favourable course of kidney disease. Whether
age by itself does account for this cannot be decided
from our analysis. Not many long-term epidemiological
data exist regarding age at onset of diabetes. A trend
towards younger age at diagnosis has been noted for
the last 15–20 years in several European countries,
such as Italy [14], Finland [15] and England [16].
Interestingly, no similar trend could be noted in our
transplant cohort, as patients tended to be older when
diagnosed with DM in later years during the time
period covered by our study (Figure 3). However, there
is a clear downward shift towards younger age at
diabetes diagnosis in patients reaching ESRD more
recently. This ﬁnding may suggest that younger age at
diagnosis is an independent risk factor contributing to a
more favourable course of diabetic nephropathy.
Alternatively, younger age at diagnosis of DM might
also reﬂect better screening efforts to detect and treat
diabetes, resulting in later occurrence and/or slower
progression of secondary complications, such as
diabetic nephropathy. However, a cautionary note is
necessary with regard to these conclusions, as no
information is available on the course of nephropathy
in diabetic patients not referred for renal transplanta-
tion. Thus, our ﬁndings are attributable exclusively to
the subgroup of transplanted diabetics assessed in this
analysis. Finally, overall improvement in medical care
Fig. 1. Cumulative incidence of ESRD in patients with type 1DM referred for transplantation: time interval from diagnosis of DM to
reaching ESRD. Patients with DM type 1 referred for transplantation have been randomized according to the year of reaching ESRD.
Time between diagnosis of DM to ESRD is displayed graphically using a failure plot that reverses the y-axis to show the number of
failures rather than the number of survivors. Comparison between groups was performed with ANOVA and post-test analysis with
Kramer–Tukey test. The results show a signiﬁcant prolongation in the median duration from onset of diabetes to renal failure for patients
referred for transplantation reaching ESRD most recently (group D).
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Fig. 2. Correlation analysis between age at diagnosis of type 1DM
and time to reach ESRD. An inverse correlation between age at
diagnosis of DM and time to reach renal failure was detectable for
all four groups (A: r¼0.43, P¼ 0.0075; B: r¼0.29, P¼ 0.0392;
C: r¼0.34, P¼ 0.0213; D: r¼0.46, P¼ 0.0036). However, for
every given age, time to develop ESRD tended to be longer in
patients with more recent occurrence of renal failure.
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and pharmacological treatment over the last decades
is likely to be the most important factor to account
for a more prolonged course to ESRD after initiation
of diabetes. Among those measures, the most likely
to have such a beneﬁcial impact are intensiﬁed
blood sugar control and insulin treatment [12],
better antihypertensive control [8], screening for
nephropathy by monitoring the occurrence of micro-
albuminuria and, last but not least, the introduction of
angiotensin-modifying drugs, such as ACE inhibitors
and angiotensin 2-receptor antagonists [9–11]. As ACE
inhibitors were approved in Switzerland in 1980,
the majority of our cohort may have been treated
with this type of drug at some time. Obviously, patients
reaching ESRD more recently were more likely to be
exposed over a longer cumulative time to ACE
inhibitors compared with patients experiencing renal
failure earlier [median duration of exposure (years):
16.1 in group D, 11.3 in group C, 6.1 in group B and 0.1
in group A].
The design of our study does not allow discriminating
the factors responsible for the apparently slower pro-
gression of kidney disease in the subgroup of diabetic
patients with nephropathy selected for renal transplan-
tation and referred more recently. Also, the ﬁndings of
our analysis may not be attributable to the overall
population of diabetics with kidney disease. In a
retrospective analysis of 1075 patients diagnosed with
juvenile type 1DM of the Allegheny County Registry,
104 (13%) developed ESRD, with a signiﬁcant decline
in 20-year cumulative incidence rate among all patients
diagnosed with diabetes between 1965 and 1969, 1970
and 1974 and 1975 and 1979 (9.1%, 4.7% and 3.6%,
respectively;P¼ 0.01) [17]. The average time from onset
of DM to ESRD, however, did not change signiﬁcantly
during the observation period among groups, but was
in a range comparable to our results (±29 years).
Although the Allegheny data may not be directly
comparable with our study, the differing ﬁndings may
suggest that type 1 diabetics referred for renal trans-
plantation may represent a positive selection of patients
with more favourable characteristics resulting in slower
progression to renal failure.
Besides the applicability strictly to patients with type
1DM undergoing kidney transplantation, our analysis
has several limitations inherent to its retrospective
design with only limited clinical data available. The
time point of ESRD occurrence may not have been
determined stringently for all patients, as we used
initiation of dialysis or date of transplantation to deﬁne
renal failure. There is no universal agreement among
physicians on when to initiate renal replacement
therapy and policies may have changed over the years.
However, in earlier days dialysis was probably started
at a later stage of renal insufﬁciency than in more recent
years. Consequently, this would be even more suppor-
tive of our notion that progression to ESRD has been
slowed over the years. Unfortunately, our data do not
allow distinguishing whether this alteration in course is
due to a change in the interval from onset of diabetes to
kidney disease or to slower progression of diabetic
nephropathy to renal failure.
Despite these limitations and to our best knowledge,
this is the ﬁrst analysis that has assessed changes
in the epidemiological characteristics and the progres-
sion of nephropathy over a time-span of almost 40
years in patients with type 1DM undergoing renal
transplantation. The ﬁndings show a trend to occur-
rence of ESRD at a later time in life, compatible with a
slower progression from onset of diabetes to renal
failure in patients referred for transplantation. The
reasons for this development are, as yet, unclear
and will have to be evaluated further. However, the
epidemiological implications are of relevance, as
the change in progression to ESRD has already resulted
in a substantially higher age at renal transplantation.
This has a beneﬁcial impact with regard to organ
shortage.
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